| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Unicycive Therapeutics Inc. | Oxylanthanum Carbonate (OLC) | Kidney disease | PDUFA | Ongoing | Oral | N/A |
| Unicycive Therapeutics Inc. | Renazorb (Fosrenol bioequivalent) | Hyperphosphatemia | NDA Filing | Ongoing | Oral | N/A |
| Unicycive Therapeutics Inc. | Renazorb (Fosrenol bioequivalent) | Hyperphosphatemia | NDA Filing | Ongoing | Oral | N/A |
| United Therapeutics Corporation | TYVASO (treprostinil) - (TETON) | Idiopathic Pulmonary Fibrosis | Phase 3 | Inhalation | Respiratory | |
| United Therapeutics Corporation | Ralinepag - (ADVANCE OUTCOMES) | Pulmonary Arterial Hypertension | Phase 3 | Oral | Cardiology | |
| United Therapeutics Corporation | Tyvaso (treprostinil) - (TETON PPF) | Progressive pulmonary fibrosis (PPF) | Phase 3 | Ongoing | Inhalation | Respiratory |
| United Therapeutics Corporation | TYVASO (treprostinil) - (TETON 2) | Idiopathic Pulmonary Fibrosis | Phase 3 | Data Released | Inhalation | Respiratory |
| United Therapeutics Corporation | Unituxin - DISTINCT | Small cell lung cancer | Phase 2/3 | Intravenous | Oncology |